Aspira Women's Health

Discover how our approach helps determine the best course of action for pelvic masses identified on ultrasound. From evaluating risks to considering surgical options, Aspira Women's Health can help you enhance your clinical triage process for pelvic masses and ovarian care.   We’d love to connect with you! Discover how we can seamlessly integrate our suite of non-invasive risk assessment tools into your practice. Reach out to us here for more information: https://lnkd.in/e97K3dTv   #OvarianCancerAwareness #OBGYN #OvarianCancer #OvaWatch #Ova1 #OvaSuite #AspiraWomensHealth #WomensHealth #PelvicMass

Introducing the latest "OvaView" summary with Victoria Haverbusch, our expert in risk assessment. In this brief video, Victoria simplifies the complexities of managing adnexal masses and highlights how Aspira Women's Health is revolutionizing care with our non-invasive tool, OvaWatch. This innovative solution enables providers to offer ongoing, point-in-time, personalized ovarian cancer risk assessments for patients under active surveillance or watchful waiting for their adnexal mass. Discover the latest advancements in biomarker technology for ovarian cancer risk assessment and gain valuable insights to support your clinical decision-making. Watch more OvaView videos here: https://lnkd.in/dTBm3zry #OvaView #AspiraWomensHealth #OvarianCancerAwareness #OvarianCancer #WomensHealth #OvaWatch

ICYMI: Aspira Women's Health recently reported our Q2 2024 Financial Results with highlights including $2.4 million in OvaSuite℠ revenue, 6,471 units in volume, and a 16% decrease in cash utilization compared to Q1 2024. Our full-year cash guidance is now $13-$14.5 million. Missed our call? Catch the replay to get the latest updates on our progress. For more details, check out our full press release here: https://lnkd.in/exsv4c3A #WomensHealth #OvarianCancer #AspiraWomensHealth #PR #InvestorUpdates

Don’t miss our second quarter earnings! Join us today at 4:30 p.m. ET for a conference call where we'll discuss financial results and provide a corporate update. A webcast replay will also be available on the Events & Presentation page of our Investor Relations website. Dial 877-407-4018 or access the webcast here: https://lnkd.in/dQC_xfcg #AspiraWomensHealth #EarningsCall #CorporateUpdate #Q2

Curious about how OvaSuite℠ can refine your approach to adnexal masses? Here are the top 5 reasons to integrate OvaSuite into your practice. Dive deeper into how OvaSuite can improve your patient's ovarian health journey here: https://lnkd.in/eRZYEW3A #AspiraWomensHealth #OvarianCancerAwareness #OvarianCancer #WomensHealth #OvaWatch #Ova1 #OvaSuite

Exciting News! Aspira Women’s Health is set to present at the 27th Annual National Association of Nurse Practitioners in Women's Health (NPWH) Women’s Healthcare Conference! Join us on September 26-27, 2024, in Chicago, IL, for a groundbreaking presentation by our VP of Research & Development, Dr. Todd Pappas, showcasing the association of the Endometriosis Health Profile-5 (EHP-5) with non-invasive biomarkers in patients with suspected endometriosis. Discover the latest advancements in endometriosis research and diagnostics. Learn more in our latest PR: https://lnkd.in/eHHk8VF8 #AspiraWomensHealth #Endometriosis #NPWH #WomensHealth #Endo #EndoAwareness #whnp #nursepractitioner

Exciting News! Aspira Women’s Health is set to present at the The Menopause Society's 2024 Annual Meeting! Join us on Thursday, September 12, 2024, in Chicago, IL, for a groundbreaking presentation by Dr. Christina Kronfel, showcasing how OvaWatch is transforming ovarian cancer risk assessment for pre- and post-menopausal women. Discover the power of deep neural network-based algorithms in evaluating indeterminate adnexal masses. Learn more in our latest PR: https://lnkd.in/edRpcDdg #AspiraWomensHealth #OvaWatch #OvarianCancer #MenopauseSociety #WomensHealth #MedicalInnovation #Chicago2024

This is outstanding news for women and girls! Sandra Elaine Brooks, MD, MBA is a force of nature. As the leader of the most important professional organization for gynecology and obstetrics, she will undoubtedly demonstrate the same sense of urgency, progress and innovation that she brings to everything she does. I call on everyone working in women’s health - and everyone that loves a person with female reproductive organs - to step up in support of Dr. Brooks and #ACOG. #obgyn #womenshealth

Join us for a conference call at 4:30 p.m. ET to discuss the financial results and get a corporate update. 📅 Date: Monday, August 12, 2024 🕟 Time: 4:30 p.m. ET 📞 Toll-Free: 877-407-4018 💻 Webcast (click here): https://lnkd.in/dQC_xfcg A replay of the webcast will be available on the Events & Presentation page of the Aspira Women’s Health Investor Relations website. Stay tuned for more updates! #AspiraWomensHealth #EarningsCall #InvestorRelations #Healthcare #WomensHealth

Aspira Women’s Health is pleased to announce the appointment of John Ragard to our Board of Directors. With over 46 years of significant public equity investment and Wall Street experience, John brings invaluable expertise to our team. We look forward to his insights as we continue our mission to deliver a new standard of care in women's health. Welcome, John! For more details, check out the press release here: https://lnkd.in/eWtqeKw9 #AspiraWomensHealth #WomensHealth #PR